PHTPP 10 mg | 99.72%
TargetMol
PHTPP
Search Results
PHTPP 5 mg | 99.72%
TargetMol
PHTPP
PHTPP 2 mg | 99.72%
TargetMol
PHTPP
Sitravatinib 200 mg | 98.90%
TargetMol
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
More Information Supplier PageSitravatinib
Sitravatinib 100 mg | 98.90%
TargetMol
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
More Information Supplier PageSitravatinib
FX1 2 mg | 99.68%
TargetMol
FX1
Pentostatin 100 mg | 99.47%
TargetMol
Pentostatin is an extremely effective and irreversible inhibitor of adenosine deaminase (Ki: 2.5 pM).
More Information Supplier PagePentostatin
TOFA 200 mg | 99.71%
TargetMol
TOFA
ICA-069673 2 mg | 99.66%
TargetMol
ICA-069673 is an activator of KCNQ2/Q3 potassium channel (IC50: 0.69 μM).
More Information Supplier PageICA-069673
Astragaloside II 25 mg | 99.70%
TargetMol
Astragaloside II is an effective MDR reversal agent and may be a potential adjunctive agent for hepatic cancer chemotherapy. Astragaloside II also induces osteogenic activities, differentiation, proliferation, and mineralization, through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.
More Information Supplier PageAstragaloside II
